[6] [7] In the safety analyses from clinical trials, cancer cases were reported in both tirzepatide-treated patients and placebo groups
Subjects and methods Subjects This randomized, single-blinded, placebo-controlled clinical study was conducted in MetS patients at the First Affiliated Hospital of Sun Yat-Sen University in Guang Zhou, China and has been registered with the Chinese Clinical Trial Registry (No
Semaglutide acts by binding to the GLP-1 receptors, which are primarily located in the pancreas
Nishida Y, MD, PhD, Ishizawa J, MD, PhD, Ayoub E, PhD, Patsilevas T, BS, Ostermann L, Montoya RH, BS, Muftuoglu M, MD, Ruvolo V, MS, Mak PY, Tao W, Carter BZ, PhD, Kojima K, MD, PhD, Daver N, MD, Lesegretain A, Seki T, PhD, Shacham S, PhD, MBA, Konopleva M, MD, PhD, Andreeff M , MD, PhD